ADMA Biologics Inc $ADMA Shares Bought by Algert Global LLC

Key Points

• Algert Global increased its ADMA Biologics stake by 118.3% in the second quarter, buying 421,247 additional shares to own 777,189 shares valued at approximately $6.5 million. Institutional investors collectively hold 75.68% of the company.
• ADMA reported second-quarter earnings of $0.16 per share, in line with estimates, while revenue reached $124.39 million, slightly below expectations but up 2% year over year. Analysts forecast full-year EPS of $0.78.
• The stock opened at $9.63, well below its 52-week high of $20.46. Analyst sentiment is mixed, resulting in a consensus “Hold” rating and an average price target of $18.67.

Algert Global LLC increased its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 118.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 777,189 shares of the biotechnology company's stock after buying an additional 421,247 shares during the quarter. Algert Global LLC owned about 0.34% of ADMA Biologics worth $6,505,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of ADMA. BlackRock Inc. acquired a new position in ADMA Biologics during the second quarter worth about $321,037,000. State Street Corp boosted its position in shares of ADMA Biologics by 0.3% during the 4th quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company's stock valued at $248,014,000 after purchasing an additional 35,614 shares in the last quarter. Sachem Head Capital Management LP boosted its position in shares of ADMA Biologics by 27.0% during the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company's stock valued at $207,480,000 after purchasing an additional 2,415,000 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in shares of ADMA Biologics by 36.9% in the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company's stock worth $127,551,000 after purchasing an additional 1,886,105 shares during the last quarter. Finally, Capital Research Global Investors grew its stake in shares of ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company's stock worth $121,067,000 after purchasing an additional 3,383,559 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Down 0.9%

ADMA Biologics stock opened at $9.63 on Thursday. The company has a 50 day moving average price of $9.03 and a 200 day moving average price of $10.60. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $20.46. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of 13.76 and a beta of 0.74.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The company's revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.14 EPS. Research analysts forecast that ADMA Biologics Inc will post 0.78 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on ADMA. Raymond James Financial initiated coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They set an "outperform" rating and a $21.00 target price for the company. Zacks Research downgraded ADMA Biologics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, August 4th. Canaccord Genuity Group cut their price objective on ADMA Biologics from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, May 7th. Weiss Ratings reissued a "hold (c)" rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Finally, Wall Street Zen cut ADMA Biologics from a "buy" rating to a "hold" rating in a report on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, ADMA Biologics currently has a consensus rating of "Hold" and an average price target of $18.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source